Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors

PURPOSE: Although EGF receptor tyrosine kinase inhibitors (EGFR-TKI) have shown dramatic effects against EGFR mutant lung cancer, patients ultimately develop resistance by multiple mechanisms. We therefore assessed the ability of combined treatment with the Met inhibitor crizotinib and new generatio...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Nanjo, Shigeki, Yamada, Tadaaki, Nishihara, Hiroshi, Takeuchi, Shinji, Sano, Takako, Nakagawa, Takayuki, Ishikawa, Daisuke, Zhao, Lu, Ebi, Hiromichi, Yasumoto, Kazuo, Matsumoto, Kunio, Yano, Seiji
Formato: Artigo
Idioma:Inglês
Publicado: Public Library of Science 2013
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3873434/
https://ncbi.nlm.nih.gov/pubmed/24386407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0084700
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares